Elixir Associates reposted this
Headhunting Talented Individuals within Clinical Operations & Clinical Development for growing organizations across the US & Europe
Bayer has achieved a significant breakthrough with their recent Phase III ARANOTE trial of Nubeqa (darolutamide). For patients with metastatic hormone-sensitive prostate cancer (mHSPC), combining Nubeqa with androgen deprivation therapy (ADT) has shown significant benefits. The trial met its primary goal of extending radiological progression-free survival (rPFS) compared to those on placebo plus ADT 🚀 This achievement signals a substantial delay in tumour growth and spread, offering more tailored treatment options for patients. With a safe profile and no new safety concerns, Nubeqa continues to affirm its potential in transforming prostate cancer therapy. Detailed results that also cover overall survival, time to treatment failure, and quality of life are eagerly awaited at an upcoming scientific conference - positive news in the world of Oncology research! 📊✅ #Bayer #ProstateCancer #ClinicalResearch #Nubeqa #LifeSciences #HealthcareInnovation #OncologyResearch #LifeScience #ElixirAssociates #StaffingPartner